ClinicalTrials.gov
ClinicalTrials.gov Menu

Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01335204
Recruitment Status : Terminated
First Posted : April 14, 2011
Last Update Posted : March 21, 2013
Sponsor:
Collaborator:
Peregrine Pharmaceuticals
Information provided by (Responsible Party):
Michael Lilly, Medical University of South Carolina

Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Terminated
  Actual Primary Completion Date : March 2013
  Actual Study Completion Date : March 2013

Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 May 7, 2018